{"gene":"FGG","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2004,"finding":"A nonsense mutation in FGG (Arg134Xaa), encoded by adjacent exons (TG-intron 4-A), does not affect mRNA splicing or stability but produces an unstable, severely truncated fibrinogen gamma chain that is not incorporated into a functional fibrinogen hexamer, demonstrating that the gamma chain C-terminal region is required for hexamer assembly.","method":"Expression studies in COS-7 cells with mutant FGG cDNA; Western blot and functional assembly assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based expression with functional readout (assembly failure), single lab, two orthogonal methods (mRNA stability + protein assembly)","pmids":["15284111"],"is_preprint":false},{"year":2005,"finding":"A missense mutation W253C (W227C in mature protein) in the C-terminal globular domain of the FGG gamma chain allows intracellular hexamer assembly but abolishes secretion into the media, establishing that the gamma chain globular domain contains determinants required for fibrinogen secretion that are distinct from those required for hexamer assembly.","method":"Co-expression of mutant FGG cDNA with wild-type FGA and FGB in cell-based system; ELISA of media and cell lysates","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution-style co-expression with functional secretion readout, single lab, two orthogonal methods (ELISA + assembly assay)","pmids":["16141000"],"is_preprint":false},{"year":2010,"finding":"A splice-site mutation FGG IVS3-2A>G causes production of two aberrant gamma-chain mRNAs (one retaining intron 3, one using a cryptic splice site in exon 4), contributing to hypofibrinogenemia through loss of normal gamma-chain production.","method":"Minigene transfection into CHO cells; RT-PCR and agarose gel electrophoresis of mRNA products","journal":"Clinica chimica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene splicing assay in CHO cells, single lab, two orthogonal methods (RT-PCR + sequencing)","pmids":["20580695"],"is_preprint":false},{"year":2013,"finding":"Heterozygous nonsense mutations in FGG (γ23X and γ376X) cause hypofibrinogenemia through nonsense-mediated mRNA decay (NMD): mutant mRNA levels are reduced in CHO cells and restored upon cycloheximide (NMD inhibitor) treatment. The truncated γ376X chain is produced but not assembled into intact fibrinogen.","method":"Minigene transfection into CHO cells; real-time quantitative RT-PCR with and without cycloheximide; immunoblot of cell lysates; ELISA","journal":"Thrombosis research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — minigene NMD assay with pharmacological inhibitor rescue plus protein-level validation, multiple orthogonal methods in single rigorous study","pmids":["24011387"],"is_preprint":false},{"year":2016,"finding":"A deep intronic FGG mutation (IVS-8 deletion, c.1129+62_65 del AATA) causes aberrant splicing producing unspliced products alongside normal product, leading to hypofibrinogenemia likely via NMD; a second mutation (Ex-9 deletion, c.1299+4 del A) abolishes normal γA- and γ'-chain production but promotes augmented aberrant γ'-chain secretion more effectively than normal fibrinogen, establishing the Ex-9 region as required for normal γ'-chain regulation.","method":"Minigene transfection into CHO cells; RT-PCR; establishment of stable CHO cell lines producing recombinant variant fibrinogen; Western blot","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene and stable cell line expression with multiple readouts, single lab","pmids":["27837696"],"is_preprint":false},{"year":2019,"finding":"FGG overexpression in SK-HEP-1 hepatocellular carcinoma cells promotes migration and invasion through activation of epithelial-to-mesenchymal transition (EMT) by upregulating Slug and ZEB1; FGG knockdown inhibits these phenotypes.","method":"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell and wound healing assays; Western blot for EMT markers (Slug, ZEB1)","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — loss-of-function and gain-of-function with defined cellular phenotype and pathway marker readout, single lab, two complementary assays","pmids":["30863175"],"is_preprint":false},{"year":2022,"finding":"A homozygous 403 bp duplication of the FGG exon 8-intron 8 junction, which duplicates the donor splice site of intron 8, causes production of several aberrant FGG transcripts containing premature truncating codons, resulting in congenital afibrinogenemia through loss of functional gamma-chain production.","method":"Minigene transfection into cells; mRNA analysis showing aberrant splicing products; whole exome sequencing with PCR confirmation","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene splicing assay with sequencing validation, single lab, two orthogonal methods","pmids":["34196169"],"is_preprint":false},{"year":2022,"finding":"A FGG c.8G>A mutation in the signal peptide-encoding exon 1 results in lower fibrin polymerization maximal absorbance, prolonged fibrinolysis, and altered fibrin clot ultrastructure (by SEM), with mass spectrometry detecting oxidative post-translational modifications on fibrinogen, collectively causing hypofibrinogenemia associated with thrombosis.","method":"Fibrin polymerization assay; fibrinolysis assay; scanning electron microscopy; mass spectrometry for PTM detection","journal":"Blood coagulation & fibrinolysis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays (polymerization, fibrinolysis, SEM, MS-PTM), single lab, single case","pmids":["35067535"],"is_preprint":false},{"year":2024,"finding":"A novel missense mutation FGG c.1168G>T impairs recombinant fibrinogen synthesis, secretion, and thrombin-catalyzed polymerization in CHO cell lines, with in silico analysis indicating disruption of hydrogen bonding and the 'A:a' knob-hole interaction required for fibrin polymerization.","method":"Recombinant fibrinogen-producing CHO cell lines; Western blot; ELISA; thrombin-catalyzed fibrin polymerization assay; in silico structural analysis","journal":"Hereditas","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based expression with multiple functional readouts (synthesis, secretion, polymerization), single lab","pmids":["38233949"],"is_preprint":false},{"year":2006,"finding":"A heterozygous FGG mutation Ala341Asp (Fibrinogen Seoul) causes defective thrombin-catalyzed fibrin polymerization as assessed by analysis of purified fibrinogen from the propositus, with molecular modeling indicating a conformational change in fibrinogen structure.","method":"Purified fibrinogen polymerization analysis; molecular modeling","journal":"Clinical and applied thrombosis/hemostasis","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional polymerization assay on purified protein, single method, single case","pmids":["16959688"],"is_preprint":false},{"year":2012,"finding":"A novel regulatory element (PFE2) located between the FGA and FGG genes acts as a liver-specific enhancer: it enhances minimal promoter- and FGA promoter-driven gene expression in hepatoma cells regardless of orientation, and drives enhanced GFP expression specifically in transgenic zebrafish larval livers in vivo.","method":"Luciferase reporter assay in hepatoma cells; transgenic zebrafish in vivo enhancer assay; ChIP-seq data integration","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo enhancer assays, single lab, two orthogonal systems (cell reporter + transgenic zebrafish)","pmids":["22836734"],"is_preprint":false},{"year":2020,"finding":"FGG participates in anthracycline chemoresistance in breast cancer cells; ligustrazine (TMP) reverses epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression, with FGG knockdown reducing chemoresistance and cancer stem cell characteristics.","method":"FGG overexpression/knockdown in chemoresistant breast cancer cell lines; JAK2/STAT3 pathway inhibition; cell viability and cancer stem cell assays","journal":"American journal of cancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — loss-of-function with cellular phenotype but pathway placement relies on pharmacological inhibitor without direct FGG-JAK2/STAT3 interaction demonstration, single lab","pmids":["32266101"],"is_preprint":false},{"year":2026,"finding":"FGG directly regulates hepatic stellate cell (HSC) activation state and promotes macrophage polarization toward the M2 phenotype; FGG overexpression in mice promotes liver fibrosis development, while siRNA-mediated FGG knockdown via AEAA-LNP inhibits HSC activation, disrupts HSC-M2 macrophage crosstalk, and alleviates biliary duct ligation (BDL)-induced liver fibrosis in vitro and in vivo.","method":"BDL mouse model; LX2-THP-1 co-culture system; FGG overexpression mouse model; siRNA knockdown via lipid nanoparticles; qRT-PCR, Western blot, RNA-seq, immunofluorescence for HSC activation and macrophage polarization markers","journal":"Journal of nanobiotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain-of-function and siRNA loss-of-function with defined cellular phenotypes and multiple orthogonal methods, single lab","pmids":["42001119"],"is_preprint":false}],"current_model":"FGG encodes the fibrinogen gamma chain, which is required for both intracellular hexamer assembly and secretion of functional fibrinogen; the C-terminal globular domain governs secretion independently of assembly, NMD degrades gamma-chain transcripts bearing premature stop codons, and splicing mutations at intron-exon junctions produce aberrant transcripts causing quantitative deficiency. Beyond hemostasis, the gamma chain promotes hepatic stellate cell activation and M2 macrophage polarization driving liver fibrosis, and enhances tumor cell migration/invasion via EMT through Slug/ZEB1 upregulation. Fibrinogen gamma chain expression is regulated by a liver-specific enhancer element (PFE2) located between FGA and FGG."},"narrative":{"mechanistic_narrative":"FGG encodes the fibrinogen gamma chain, a subunit required for both intracellular assembly of the fibrinogen hexamer and its secretion as a functional clotting factor [PMID:15284111, PMID:16141000]. The C-terminal globular domain of the gamma chain is functionally partitioned: it is required for hexamer assembly [PMID:15284111], while distinct determinants within the same domain govern secretion independently of assembly, since a globular-domain missense mutation permits intracellular assembly yet abolishes secretion [PMID:16141000]. Once secreted, the gamma chain contributes the 'A:a' knob-hole interaction and conformational determinants needed for thrombin-catalyzed fibrin polymerization and normal clot architecture, and point mutations in this region produce dysfunctional polymerization, altered clot ultrastructure, and prolonged fibrinolysis [PMID:35067535, PMID:38233949]. Loss-of-function alleles cause quantitative deficiency through several routes: nonsense mutations bearing premature stop codons trigger nonsense-mediated mRNA decay [PMID:24011387], and splice-site, deep-intronic, and junction-duplication mutations generate aberrant transcripts that lose normal gamma-chain (and gamma'-chain) production, causing hypofibrinogenemia and congenital afibrinogenemia [PMID:20580695, PMID:27837696, PMID:34196169]. Hepatic FGG expression is controlled by PFE2, a liver-specific enhancer located between FGA and FGG [PMID:22836734]. Beyond hemostasis, FGG promotes tumor cell migration and invasion via EMT through Slug and ZEB1 upregulation [PMID:30863175], and drives liver fibrosis by activating hepatic stellate cells and promoting M2 macrophage polarization [PMID:42001119].","teleology":[{"year":2004,"claim":"Established that the gamma-chain C-terminal region is required for assembly of fibrinogen into a functional hexamer, distinguishing assembly defects from transcript-level defects.","evidence":"Expression of a nonsense mutant (Arg134Xaa) FGG cDNA in COS-7 cells with mRNA stability and protein assembly readouts","pmids":["15284111"],"confidence":"Medium","gaps":["Does not map the precise residues mediating chain-chain contacts","Single cell-based system without structural confirmation"]},{"year":2005,"claim":"Resolved that secretion of assembled fibrinogen is governed by determinants in the gamma-chain globular domain that are separable from assembly determinants.","evidence":"Co-expression of W253C mutant FGG with wild-type FGA and FGB in cells; ELISA of media versus lysates","pmids":["16141000"],"confidence":"Medium","gaps":["Mechanism of the secretion block (folding, trafficking, retention) not defined","Single missense allele"]},{"year":2006,"claim":"Linked a specific gamma-chain residue substitution to defective thrombin-catalyzed polymerization at the level of clot formation.","evidence":"Polymerization analysis of purified fibrinogen from a patient (Fibrinogen Seoul, Ala341Asp) plus molecular modeling","pmids":["16959688"],"confidence":"Low","gaps":["Single method on a single patient sample without recombinant validation","Conformational change inferred from modeling, not measured"]},{"year":2010,"claim":"Showed that splice-site mutations produce aberrant gamma-chain transcripts as a route to hypofibrinogenemia, beyond coding-region defects.","evidence":"Minigene transfection of IVS3-2A>G in CHO cells; RT-PCR of mRNA products","pmids":["20580695"],"confidence":"Medium","gaps":["Does not quantify protein-level consequences","Fate of aberrant transcripts (NMD vs. translation) not addressed"]},{"year":2012,"claim":"Identified the cis-regulatory basis of liver-specific FGG expression by characterizing the intergenic PFE2 enhancer.","evidence":"Luciferase reporter assays in hepatoma cells and transgenic zebrafish in vivo enhancer assay with ChIP-seq integration","pmids":["22836734"],"confidence":"Medium","gaps":["Transcription factors binding PFE2 not identified","Contribution to FGG versus FGA regulation not separated"]},{"year":2013,"claim":"Demonstrated that premature-stop-codon FGG alleles cause deficiency through nonsense-mediated mRNA decay, not solely defective protein.","evidence":"Minigene transfection in CHO cells with cycloheximide rescue, qRT-PCR, immunoblot, and ELISA","pmids":["24011387"],"confidence":"High","gaps":["Allele-specific contribution of NMD versus protein instability not quantified per variant","In vivo confirmation in patient hepatocytes absent"]},{"year":2016,"claim":"Extended the deficiency mechanism to deep-intronic and junction deletions and identified the Ex-9 region as required for normal gamma'-chain regulation.","evidence":"Minigene transfection and stable recombinant CHO cell lines; RT-PCR and Western blot of gammaA and gamma' chains","pmids":["27837696"],"confidence":"Medium","gaps":["Functional consequence of augmented gamma'-chain secretion not assessed","Mechanism by which Ex-9 controls gamma' splicing not defined"]},{"year":2019,"claim":"Established a non-hemostatic, pro-metastatic role for FGG in driving EMT-dependent tumor cell migration and invasion.","evidence":"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell/wound healing assays; Western blot for Slug and ZEB1","pmids":["30863175"],"confidence":"Medium","gaps":["Direct molecular link between FGG and Slug/ZEB1 induction not defined","In vivo metastasis not tested"]},{"year":2020,"claim":"Implicated FGG in anthracycline chemoresistance and cancer stem cell traits in breast cancer.","evidence":"FGG overexpression/knockdown in chemoresistant breast cancer lines with JAK2/STAT3 pharmacological inhibition and viability/stemness assays","pmids":["32266101"],"confidence":"Low","gaps":["JAK2/STAT3 placement relies on inhibitor without direct FGG-pathway interaction","Single lab, not independently confirmed"]},{"year":2022,"claim":"Confirmed that a junction-duplicating mutation generates premature-stop transcripts causing congenital afibrinogenemia, reinforcing aberrant-splicing as a deficiency mechanism.","evidence":"Minigene transfection, mRNA analysis, and whole exome sequencing with PCR confirmation of a 403 bp exon 8-intron 8 duplication","pmids":["34196169"],"confidence":"Medium","gaps":["NMD versus truncated-protein contribution not directly tested","Single family"]},{"year":2022,"claim":"Connected a signal-peptide-region mutation to altered fibrin polymerization, clot ultrastructure, fibrinolysis, and oxidative PTMs in a thrombosis-associated hypofibrinogenemia.","evidence":"Fibrin polymerization and fibrinolysis assays, SEM clot imaging, and mass spectrometry PTM detection on patient fibrinogen","pmids":["35067535"],"confidence":"Medium","gaps":["Causal link between signal-peptide variant and oxidative PTMs unresolved","Single case"]},{"year":2024,"claim":"Mapped a missense variant to the 'A:a' knob-hole interaction, mechanistically tying a structural contact to impaired synthesis, secretion, and polymerization.","evidence":"Recombinant fibrinogen CHO cell lines with Western blot, ELISA, thrombin-catalyzed polymerization, and in silico structural analysis of c.1168G>T","pmids":["38233949"],"confidence":"Medium","gaps":["Structural disruption inferred in silico, not by experimental structure","Single variant"]},{"year":2026,"claim":"Defined an active role for FGG in liver fibrosis through hepatic stellate cell activation and M2 macrophage polarization, identifying it as a therapeutic target.","evidence":"BDL mouse model, LX2-THP-1 co-culture, FGG overexpression mice, and AEAA-LNP siRNA knockdown with multi-omic and imaging readouts","pmids":["42001119"],"confidence":"Medium","gaps":["Direct molecular receptor/effector mediating HSC-macrophage crosstalk not identified","Single lab"]},{"year":null,"claim":"How the gamma chain's hemostatic role mechanistically connects to its pro-fibrotic and pro-tumorigenic signaling functions remains unresolved.","evidence":"No discovery in the corpus links the secreted/structural fibrinogen function to a defined receptor or signaling cascade driving EMT or HSC activation","pmids":[],"confidence":"Low","gaps":["No cell-surface receptor for FGG signaling identified","No structural model of full-length gamma chain in the corpus","Transcription factors controlling PFE2 enhancer unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,7,8]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,7,8]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,7,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,6,12]}],"complexes":["fibrinogen hexamer"],"partners":["FGA","FGB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02679","full_name":"Fibrinogen gamma chain","aliases":[],"length_aa":453,"mass_kda":51.5,"function":"Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02679/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGG","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGG","total_profiled":1310},"omim":[{"mim_id":"616004","title":"DYSFIBRINOGENEMIA, CONGENITAL","url":"https://www.omim.org/entry/616004"},{"mim_id":"605776","title":"FIBRINOGEN-LIKE 1; FGL1","url":"https://www.omim.org/entry/605776"},{"mim_id":"605351","title":"FIBRINOGEN-LIKE 2; FGL2","url":"https://www.omim.org/entry/605351"},{"mim_id":"603924","title":"HYALURONAN-BINDING PROTEIN 2; HABP2","url":"https://www.omim.org/entry/603924"},{"mim_id":"603826","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 4; NR1H4","url":"https://www.omim.org/entry/603826"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":15475.1}],"url":"https://www.proteinatlas.org/search/FGG"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02679","domains":[{"cath_id":"3.90.215.10","chopping":"178-421","consensus_level":"high","plddt":96.8441,"start":178,"end":421},{"cath_id":"1.20.5","chopping":"45-95","consensus_level":"medium","plddt":80.3924,"start":45,"end":95},{"cath_id":"1.20.5","chopping":"106-156","consensus_level":"medium","plddt":94.3227,"start":106,"end":156}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02679","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02679-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02679-F1-predicted_aligned_error_v6.png","plddt_mean":85.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGG","jax_strain_url":"https://www.jax.org/strain/search?query=FGG"},"sequence":{"accession":"P02679","fasta_url":"https://rest.uniprot.org/uniprotkb/P02679.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02679/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02679"}},"corpus_meta":[{"pmid":"11354637","id":"PMC_11354637","title":"Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11354637","citation_count":62,"is_preprint":false},{"pmid":"32610551","id":"PMC_32610551","title":"Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32610551","citation_count":55,"is_preprint":false},{"pmid":"19596924","id":"PMC_19596924","title":"Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma.","date":"2009","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19596924","citation_count":52,"is_preprint":false},{"pmid":"30863175","id":"PMC_30863175","title":"FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30863175","citation_count":41,"is_preprint":false},{"pmid":"17445871","id":"PMC_17445871","title":"The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.","date":"2007","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/17445871","citation_count":35,"is_preprint":false},{"pmid":"31576477","id":"PMC_31576477","title":"FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.","date":"2019","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31576477","citation_count":31,"is_preprint":false},{"pmid":"15284111","id":"PMC_15284111","title":"Expression and analysis of a split premature termination codon in FGG responsible for congenital afibrinogenemia: escape from RNA surveillance mechanisms in transfected cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15284111","citation_count":26,"is_preprint":false},{"pmid":"16141000","id":"PMC_16141000","title":"Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16141000","citation_count":25,"is_preprint":false},{"pmid":"24011387","id":"PMC_24011387","title":"Nonsense-mediated mRNA decay was demonstrated in two hypofibrinogenemias caused by heterozygous nonsense mutations of FGG, Shizuoka III and Kanazawa II.","date":"2013","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/24011387","citation_count":15,"is_preprint":false},{"pmid":"8428520","id":"PMC_8428520","title":"The gamma fibrinogen gene (FGG) maps to chromosome 17 in both cattle and sheep.","date":"1993","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8428520","citation_count":14,"is_preprint":false},{"pmid":"22836734","id":"PMC_22836734","title":"A novel regulatory element between the human FGA and FGG genes.","date":"2012","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/22836734","citation_count":14,"is_preprint":false},{"pmid":"32266101","id":"PMC_32266101","title":"Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32266101","citation_count":14,"is_preprint":false},{"pmid":"28318107","id":"PMC_28318107","title":"The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG-Arg301 to be distinguished from hypofibrinogenemia.","date":"2017","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28318107","citation_count":10,"is_preprint":false},{"pmid":"26686377","id":"PMC_26686377","title":"Construction of supramolecular polymer by enzyme-triggered covalent condensation of CB[8]-FGG-based supramonomer.","date":"2016","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26686377","citation_count":10,"is_preprint":false},{"pmid":"20580695","id":"PMC_20580695","title":"In vitro transcription of compound heterozygous hypofibrinogenemia Matsumoto IX; first identification of FGB IVS6 deletion of 4 nucleotides and FGG IVS3-2A>G causing abnormal RNA splicing.","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20580695","citation_count":9,"is_preprint":false},{"pmid":"16959688","id":"PMC_16959688","title":"Fibrinogen Seoul (FGG Ala341Asp): a novel mutation associated with hypodysfibrinogenemia.","date":"2006","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/16959688","citation_count":8,"is_preprint":false},{"pmid":"27999448","id":"PMC_27999448","title":"Thrombosis Related ABO, F5, MTHFR, and FGG Gene Polymorphisms in Morbidly Obese Patients.","date":"2016","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27999448","citation_count":7,"is_preprint":false},{"pmid":"29769041","id":"PMC_29769041","title":"Cortical atrophy and hypofibrinogenemia due to FGG and TBCD mutations in a single family: a case report.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29769041","citation_count":7,"is_preprint":false},{"pmid":"27837696","id":"PMC_27837696","title":"Genetic analyses of novel compound heterozygous hypodysfibrinogenemia, Tsukuba I: FGG c.1129+62_65 del AATA and FGG c.1299+4 del A.","date":"2016","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/27837696","citation_count":7,"is_preprint":false},{"pmid":"38708173","id":"PMC_38708173","title":"Factor VII R353Q (rs6046), FGA A6534G (rs6050), and FGG C10034T (rs2066865) Gene Polymorphisms and Risk of Recurrent Pregnancy Loss in Iranian Women.","date":"2023","source":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/38708173","citation_count":6,"is_preprint":false},{"pmid":"37124494","id":"PMC_37124494","title":"Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adenocarcinoma.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37124494","citation_count":6,"is_preprint":false},{"pmid":"31484330","id":"PMC_31484330","title":"Polymorphism rs2066865 in the Fibrinogen Gamma Chain (FGG) Gene Increases Plasma Fibrinogen Concentration and Is Associated with an Increased Microvascular Thrombosis Rate.","date":"2019","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/31484330","citation_count":6,"is_preprint":false},{"pmid":"35067535","id":"PMC_35067535","title":"Thrombosis-associated hypofibrinogenemia: novel abnormal fibrinogen variant FGG c.8G>A with oxidative posttranslational modifications.","date":"2022","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/35067535","citation_count":6,"is_preprint":false},{"pmid":"15025951","id":"PMC_15025951","title":"[Cloning and identification of fibrinogen gamma polypeptide (FGG) gene differentially expressed in human hepatocellular carcinoma].","date":"2004","source":"Ai zheng = Aizheng = Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15025951","citation_count":4,"is_preprint":false},{"pmid":"18615659","id":"PMC_18615659","title":"The role of weakly polar and H-bonding interactions in the stabilization of the conformers of FGG, WGG, and YGG: an aqueous phase computational study.","date":"2008","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/18615659","citation_count":4,"is_preprint":false},{"pmid":"19551918","id":"PMC_19551918","title":"Recurrence of the 'deep-intronic' FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto.","date":"2009","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/19551918","citation_count":4,"is_preprint":false},{"pmid":"38327620","id":"PMC_38327620","title":"The FGG c.952G>A variant causes congenital dysfibrinogenemia characterized by recurrent cerebral infarction: a case report.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38327620","citation_count":3,"is_preprint":false},{"pmid":"33812435","id":"PMC_33812435","title":"[Congenital Fibrinogen Deficiency Caused by Novel FGG Gene Mutation].","date":"2021","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/33812435","citation_count":2,"is_preprint":false},{"pmid":"34196169","id":"PMC_34196169","title":"A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family.","date":"2022","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/34196169","citation_count":2,"is_preprint":false},{"pmid":"38233949","id":"PMC_38233949","title":"A novel missense mutation (FGG c.1168G > T) in the gamma chain of fibrinogen causing congenital hypodysfibrinogenemia with bleeding phenotype.","date":"2024","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/38233949","citation_count":2,"is_preprint":false},{"pmid":"31131962","id":"PMC_31131962","title":"Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male.","date":"2019","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31131962","citation_count":2,"is_preprint":false},{"pmid":"38374144","id":"PMC_38374144","title":"A novel mutation in the FGG gene causes hypofibrinogenemia in a Chinese family.","date":"2024","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/38374144","citation_count":1,"is_preprint":false},{"pmid":"40806633","id":"PMC_40806633","title":"Genetic Associations of ITGB3, FGG, GP1BA, PECAM1, and PEAR1 Polymorphisms and the Platelet Activation Pathway with Recurrent Pregnancy Loss in the Korean Population.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806633","citation_count":1,"is_preprint":false},{"pmid":"40025073","id":"PMC_40025073","title":"A familial study of a de novo FGG gene mutation causing congenital hypofibrinogenaemia and intervention during pregnancy and childbirth.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40025073","citation_count":1,"is_preprint":false},{"pmid":"40501422","id":"PMC_40501422","title":"Hereditary hepatic fibrinogen storage disease with a novel fibrinogen variant FGG c.1113T>A ( fibrinogen Seoul III ).","date":"2025","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/40501422","citation_count":1,"is_preprint":false},{"pmid":"26037343","id":"PMC_26037343","title":"[Congenital hypofibrinogenemia associated with a novel mutation in FGG gene].","date":"2015","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26037343","citation_count":0,"is_preprint":false},{"pmid":"30512152","id":"PMC_30512152","title":"[Mutation analysis of a FGG gene causing hereditary abnormal fibrinogen].","date":"2018","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30512152","citation_count":0,"is_preprint":false},{"pmid":"41030265","id":"PMC_41030265","title":"Implications of the c.1201C > G (p.Arg401Gly) mutation in FGG gene on fibrinogen stability and function.","date":"2025","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41030265","citation_count":0,"is_preprint":false},{"pmid":"42001119","id":"PMC_42001119","title":"Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis.","date":"2026","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/42001119","citation_count":0,"is_preprint":false},{"pmid":"39473893","id":"PMC_39473893","title":"Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel FGG mutation.","date":"2024","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39473893","citation_count":0,"is_preprint":false},{"pmid":"33306830","id":"PMC_33306830","title":"[A case of inherited afibrinogenemia caused by an IVS7-12A>G splice mutation of FGG gene].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33306830","citation_count":0,"is_preprint":false},{"pmid":"37906135","id":"PMC_37906135","title":"[Genetic analysis of a Chinese pedigree affected with Congenital dysfibrinogenemia due to variant of FGG gene].","date":"2023","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37906135","citation_count":0,"is_preprint":false},{"pmid":"41233956","id":"PMC_41233956","title":"Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes.","date":"2026","source":"Laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41233956","citation_count":0,"is_preprint":false},{"pmid":"41499360","id":"PMC_41499360","title":"Tuning the Viscoelasticity of Supramolecular Alginate Hydrogels via Homoternary FGG-Peptide-Cucurbit[8]uril Complexes.","date":"2026","source":"Biomacromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41499360","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.16.682426","title":"Beyond the Genotype: A Multi-Omic Analysis of APOEe4’s Role in Alzheimer’s Disease","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682426","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.15.654000","title":"Differential Proteomic Analysis of DEN-Induced Hepatocellular Carcinoma in Male and Female Balb/c Mice Reveals Novel Gender Specific Markers","date":"2025-05-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.15.654000","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24941,"output_tokens":3251,"usd":0.061794,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10813,"output_tokens":3804,"usd":0.074582,"stage2_stop_reason":"end_turn"},"total_usd":0.136376,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"A nonsense mutation in FGG (Arg134Xaa), encoded by adjacent exons (TG-intron 4-A), does not affect mRNA splicing or stability but produces an unstable, severely truncated fibrinogen gamma chain that is not incorporated into a functional fibrinogen hexamer, demonstrating that the gamma chain C-terminal region is required for hexamer assembly.\",\n      \"method\": \"Expression studies in COS-7 cells with mutant FGG cDNA; Western blot and functional assembly assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based expression with functional readout (assembly failure), single lab, two orthogonal methods (mRNA stability + protein assembly)\",\n      \"pmids\": [\"15284111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A missense mutation W253C (W227C in mature protein) in the C-terminal globular domain of the FGG gamma chain allows intracellular hexamer assembly but abolishes secretion into the media, establishing that the gamma chain globular domain contains determinants required for fibrinogen secretion that are distinct from those required for hexamer assembly.\",\n      \"method\": \"Co-expression of mutant FGG cDNA with wild-type FGA and FGB in cell-based system; ELISA of media and cell lysates\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution-style co-expression with functional secretion readout, single lab, two orthogonal methods (ELISA + assembly assay)\",\n      \"pmids\": [\"16141000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A splice-site mutation FGG IVS3-2A>G causes production of two aberrant gamma-chain mRNAs (one retaining intron 3, one using a cryptic splice site in exon 4), contributing to hypofibrinogenemia through loss of normal gamma-chain production.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR and agarose gel electrophoresis of mRNA products\",\n      \"journal\": \"Clinica chimica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene splicing assay in CHO cells, single lab, two orthogonal methods (RT-PCR + sequencing)\",\n      \"pmids\": [\"20580695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Heterozygous nonsense mutations in FGG (γ23X and γ376X) cause hypofibrinogenemia through nonsense-mediated mRNA decay (NMD): mutant mRNA levels are reduced in CHO cells and restored upon cycloheximide (NMD inhibitor) treatment. The truncated γ376X chain is produced but not assembled into intact fibrinogen.\",\n      \"method\": \"Minigene transfection into CHO cells; real-time quantitative RT-PCR with and without cycloheximide; immunoblot of cell lysates; ELISA\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — minigene NMD assay with pharmacological inhibitor rescue plus protein-level validation, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"24011387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A deep intronic FGG mutation (IVS-8 deletion, c.1129+62_65 del AATA) causes aberrant splicing producing unspliced products alongside normal product, leading to hypofibrinogenemia likely via NMD; a second mutation (Ex-9 deletion, c.1299+4 del A) abolishes normal γA- and γ'-chain production but promotes augmented aberrant γ'-chain secretion more effectively than normal fibrinogen, establishing the Ex-9 region as required for normal γ'-chain regulation.\",\n      \"method\": \"Minigene transfection into CHO cells; RT-PCR; establishment of stable CHO cell lines producing recombinant variant fibrinogen; Western blot\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene and stable cell line expression with multiple readouts, single lab\",\n      \"pmids\": [\"27837696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGG overexpression in SK-HEP-1 hepatocellular carcinoma cells promotes migration and invasion through activation of epithelial-to-mesenchymal transition (EMT) by upregulating Slug and ZEB1; FGG knockdown inhibits these phenotypes.\",\n      \"method\": \"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell and wound healing assays; Western blot for EMT markers (Slug, ZEB1)\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — loss-of-function and gain-of-function with defined cellular phenotype and pathway marker readout, single lab, two complementary assays\",\n      \"pmids\": [\"30863175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A homozygous 403 bp duplication of the FGG exon 8-intron 8 junction, which duplicates the donor splice site of intron 8, causes production of several aberrant FGG transcripts containing premature truncating codons, resulting in congenital afibrinogenemia through loss of functional gamma-chain production.\",\n      \"method\": \"Minigene transfection into cells; mRNA analysis showing aberrant splicing products; whole exome sequencing with PCR confirmation\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene splicing assay with sequencing validation, single lab, two orthogonal methods\",\n      \"pmids\": [\"34196169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A FGG c.8G>A mutation in the signal peptide-encoding exon 1 results in lower fibrin polymerization maximal absorbance, prolonged fibrinolysis, and altered fibrin clot ultrastructure (by SEM), with mass spectrometry detecting oxidative post-translational modifications on fibrinogen, collectively causing hypofibrinogenemia associated with thrombosis.\",\n      \"method\": \"Fibrin polymerization assay; fibrinolysis assay; scanning electron microscopy; mass spectrometry for PTM detection\",\n      \"journal\": \"Blood coagulation & fibrinolysis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays (polymerization, fibrinolysis, SEM, MS-PTM), single lab, single case\",\n      \"pmids\": [\"35067535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A novel missense mutation FGG c.1168G>T impairs recombinant fibrinogen synthesis, secretion, and thrombin-catalyzed polymerization in CHO cell lines, with in silico analysis indicating disruption of hydrogen bonding and the 'A:a' knob-hole interaction required for fibrin polymerization.\",\n      \"method\": \"Recombinant fibrinogen-producing CHO cell lines; Western blot; ELISA; thrombin-catalyzed fibrin polymerization assay; in silico structural analysis\",\n      \"journal\": \"Hereditas\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based expression with multiple functional readouts (synthesis, secretion, polymerization), single lab\",\n      \"pmids\": [\"38233949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A heterozygous FGG mutation Ala341Asp (Fibrinogen Seoul) causes defective thrombin-catalyzed fibrin polymerization as assessed by analysis of purified fibrinogen from the propositus, with molecular modeling indicating a conformational change in fibrinogen structure.\",\n      \"method\": \"Purified fibrinogen polymerization analysis; molecular modeling\",\n      \"journal\": \"Clinical and applied thrombosis/hemostasis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional polymerization assay on purified protein, single method, single case\",\n      \"pmids\": [\"16959688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A novel regulatory element (PFE2) located between the FGA and FGG genes acts as a liver-specific enhancer: it enhances minimal promoter- and FGA promoter-driven gene expression in hepatoma cells regardless of orientation, and drives enhanced GFP expression specifically in transgenic zebrafish larval livers in vivo.\",\n      \"method\": \"Luciferase reporter assay in hepatoma cells; transgenic zebrafish in vivo enhancer assay; ChIP-seq data integration\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo enhancer assays, single lab, two orthogonal systems (cell reporter + transgenic zebrafish)\",\n      \"pmids\": [\"22836734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGG participates in anthracycline chemoresistance in breast cancer cells; ligustrazine (TMP) reverses epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression, with FGG knockdown reducing chemoresistance and cancer stem cell characteristics.\",\n      \"method\": \"FGG overexpression/knockdown in chemoresistant breast cancer cell lines; JAK2/STAT3 pathway inhibition; cell viability and cancer stem cell assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — loss-of-function with cellular phenotype but pathway placement relies on pharmacological inhibitor without direct FGG-JAK2/STAT3 interaction demonstration, single lab\",\n      \"pmids\": [\"32266101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FGG directly regulates hepatic stellate cell (HSC) activation state and promotes macrophage polarization toward the M2 phenotype; FGG overexpression in mice promotes liver fibrosis development, while siRNA-mediated FGG knockdown via AEAA-LNP inhibits HSC activation, disrupts HSC-M2 macrophage crosstalk, and alleviates biliary duct ligation (BDL)-induced liver fibrosis in vitro and in vivo.\",\n      \"method\": \"BDL mouse model; LX2-THP-1 co-culture system; FGG overexpression mouse model; siRNA knockdown via lipid nanoparticles; qRT-PCR, Western blot, RNA-seq, immunofluorescence for HSC activation and macrophage polarization markers\",\n      \"journal\": \"Journal of nanobiotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain-of-function and siRNA loss-of-function with defined cellular phenotypes and multiple orthogonal methods, single lab\",\n      \"pmids\": [\"42001119\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGG encodes the fibrinogen gamma chain, which is required for both intracellular hexamer assembly and secretion of functional fibrinogen; the C-terminal globular domain governs secretion independently of assembly, NMD degrades gamma-chain transcripts bearing premature stop codons, and splicing mutations at intron-exon junctions produce aberrant transcripts causing quantitative deficiency. Beyond hemostasis, the gamma chain promotes hepatic stellate cell activation and M2 macrophage polarization driving liver fibrosis, and enhances tumor cell migration/invasion via EMT through Slug/ZEB1 upregulation. Fibrinogen gamma chain expression is regulated by a liver-specific enhancer element (PFE2) located between FGA and FGG.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGG encodes the fibrinogen gamma chain, a subunit required for both intracellular assembly of the fibrinogen hexamer and its secretion as a functional clotting factor [#0, #1]. The C-terminal globular domain of the gamma chain is functionally partitioned: it is required for hexamer assembly [#0], while distinct determinants within the same domain govern secretion independently of assembly, since a globular-domain missense mutation permits intracellular assembly yet abolishes secretion [#1]. Once secreted, the gamma chain contributes the 'A:a' knob-hole interaction and conformational determinants needed for thrombin-catalyzed fibrin polymerization and normal clot architecture, and point mutations in this region produce dysfunctional polymerization, altered clot ultrastructure, and prolonged fibrinolysis [#7, #8]. Loss-of-function alleles cause quantitative deficiency through several routes: nonsense mutations bearing premature stop codons trigger nonsense-mediated mRNA decay [#3], and splice-site, deep-intronic, and junction-duplication mutations generate aberrant transcripts that lose normal gamma-chain (and gamma'-chain) production, causing hypofibrinogenemia and congenital afibrinogenemia [#2, #4, #6]. Hepatic FGG expression is controlled by PFE2, a liver-specific enhancer located between FGA and FGG [#10]. Beyond hemostasis, FGG promotes tumor cell migration and invasion via EMT through Slug and ZEB1 upregulation [#5], and drives liver fibrosis by activating hepatic stellate cells and promoting M2 macrophage polarization [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that the gamma-chain C-terminal region is required for assembly of fibrinogen into a functional hexamer, distinguishing assembly defects from transcript-level defects.\",\n      \"evidence\": \"Expression of a nonsense mutant (Arg134Xaa) FGG cDNA in COS-7 cells with mRNA stability and protein assembly readouts\",\n      \"pmids\": [\"15284111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not map the precise residues mediating chain-chain contacts\", \"Single cell-based system without structural confirmation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved that secretion of assembled fibrinogen is governed by determinants in the gamma-chain globular domain that are separable from assembly determinants.\",\n      \"evidence\": \"Co-expression of W253C mutant FGG with wild-type FGA and FGB in cells; ELISA of media versus lysates\",\n      \"pmids\": [\"16141000\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of the secretion block (folding, trafficking, retention) not defined\", \"Single missense allele\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked a specific gamma-chain residue substitution to defective thrombin-catalyzed polymerization at the level of clot formation.\",\n      \"evidence\": \"Polymerization analysis of purified fibrinogen from a patient (Fibrinogen Seoul, Ala341Asp) plus molecular modeling\",\n      \"pmids\": [\"16959688\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single method on a single patient sample without recombinant validation\", \"Conformational change inferred from modeling, not measured\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed that splice-site mutations produce aberrant gamma-chain transcripts as a route to hypofibrinogenemia, beyond coding-region defects.\",\n      \"evidence\": \"Minigene transfection of IVS3-2A>G in CHO cells; RT-PCR of mRNA products\",\n      \"pmids\": [\"20580695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not quantify protein-level consequences\", \"Fate of aberrant transcripts (NMD vs. translation) not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified the cis-regulatory basis of liver-specific FGG expression by characterizing the intergenic PFE2 enhancer.\",\n      \"evidence\": \"Luciferase reporter assays in hepatoma cells and transgenic zebrafish in vivo enhancer assay with ChIP-seq integration\",\n      \"pmids\": [\"22836734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors binding PFE2 not identified\", \"Contribution to FGG versus FGA regulation not separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated that premature-stop-codon FGG alleles cause deficiency through nonsense-mediated mRNA decay, not solely defective protein.\",\n      \"evidence\": \"Minigene transfection in CHO cells with cycloheximide rescue, qRT-PCR, immunoblot, and ELISA\",\n      \"pmids\": [\"24011387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allele-specific contribution of NMD versus protein instability not quantified per variant\", \"In vivo confirmation in patient hepatocytes absent\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the deficiency mechanism to deep-intronic and junction deletions and identified the Ex-9 region as required for normal gamma'-chain regulation.\",\n      \"evidence\": \"Minigene transfection and stable recombinant CHO cell lines; RT-PCR and Western blot of gammaA and gamma' chains\",\n      \"pmids\": [\"27837696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of augmented gamma'-chain secretion not assessed\", \"Mechanism by which Ex-9 controls gamma' splicing not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a non-hemostatic, pro-metastatic role for FGG in driving EMT-dependent tumor cell migration and invasion.\",\n      \"evidence\": \"FGG overexpression and siRNA knockdown in SK-HEP-1 cells; transwell/wound healing assays; Western blot for Slug and ZEB1\",\n      \"pmids\": [\"30863175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between FGG and Slug/ZEB1 induction not defined\", \"In vivo metastasis not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated FGG in anthracycline chemoresistance and cancer stem cell traits in breast cancer.\",\n      \"evidence\": \"FGG overexpression/knockdown in chemoresistant breast cancer lines with JAK2/STAT3 pharmacological inhibition and viability/stemness assays\",\n      \"pmids\": [\"32266101\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"JAK2/STAT3 placement relies on inhibitor without direct FGG-pathway interaction\", \"Single lab, not independently confirmed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed that a junction-duplicating mutation generates premature-stop transcripts causing congenital afibrinogenemia, reinforcing aberrant-splicing as a deficiency mechanism.\",\n      \"evidence\": \"Minigene transfection, mRNA analysis, and whole exome sequencing with PCR confirmation of a 403 bp exon 8-intron 8 duplication\",\n      \"pmids\": [\"34196169\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NMD versus truncated-protein contribution not directly tested\", \"Single family\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected a signal-peptide-region mutation to altered fibrin polymerization, clot ultrastructure, fibrinolysis, and oxidative PTMs in a thrombosis-associated hypofibrinogenemia.\",\n      \"evidence\": \"Fibrin polymerization and fibrinolysis assays, SEM clot imaging, and mass spectrometry PTM detection on patient fibrinogen\",\n      \"pmids\": [\"35067535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between signal-peptide variant and oxidative PTMs unresolved\", \"Single case\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped a missense variant to the 'A:a' knob-hole interaction, mechanistically tying a structural contact to impaired synthesis, secretion, and polymerization.\",\n      \"evidence\": \"Recombinant fibrinogen CHO cell lines with Western blot, ELISA, thrombin-catalyzed polymerization, and in silico structural analysis of c.1168G>T\",\n      \"pmids\": [\"38233949\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural disruption inferred in silico, not by experimental structure\", \"Single variant\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined an active role for FGG in liver fibrosis through hepatic stellate cell activation and M2 macrophage polarization, identifying it as a therapeutic target.\",\n      \"evidence\": \"BDL mouse model, LX2-THP-1 co-culture, FGG overexpression mice, and AEAA-LNP siRNA knockdown with multi-omic and imaging readouts\",\n      \"pmids\": [\"42001119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular receptor/effector mediating HSC-macrophage crosstalk not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the gamma chain's hemostatic role mechanistically connects to its pro-fibrotic and pro-tumorigenic signaling functions remains unresolved.\",\n      \"evidence\": \"No discovery in the corpus links the secreted/structural fibrinogen function to a defined receptor or signaling cascade driving EMT or HSC activation\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No cell-surface receptor for FGG signaling identified\", \"No structural model of full-length gamma chain in the corpus\", \"Transcription factors controlling PFE2 enhancer unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 7, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 7, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 12]}\n    ],\n    \"complexes\": [\"fibrinogen hexamer\"],\n    \"partners\": [\"FGA\", \"FGB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}